Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.23B P/E - EPS this Y 25.00% Ern Qtrly Grth -
Income -490.76M Forward P/E -9.13 EPS next Y 16.20% 50D Avg Chg 2.00%
Sales 643.81M PEG -0.24 EPS past 5Y - 200D Avg Chg 7.00%
Dividend N/A Price/Book N/A EPS next 5Y 29.20% 52W High Chg -42.00%
Recommedations 1.70 Quick Ratio 5.39 Shares Outstanding 123.02M 52W Low Chg 75.00%
Insider Own 4.57% ROA -15.42% Shares Float 117.40M Beta 1.11
Inst Own 97.05% ROE -337.16% Shares Shorted/Prior 11.35M/9.39M Price 36.14
Gross Margin 59.95% Profit Margin -76.23% Avg. Volume 2,181,495 Target Price 41.16
Oper. Margin -56.60% Earnings Date Nov 4 Volume 1,897,454 Change -4.88%
About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Guardant Health, Inc. News
11/20/24 Guardant Health Stock Sees RS Rating Jump To 83
11/13/24 Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/12/24 Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11/08/24 Guardant Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
11/07/24 Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop
11/07/24 Guardant Health Inc (GH) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
11/06/24 Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
11/06/24 Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
11/06/24 Guardant Health: Q3 Earnings Snapshot
11/06/24 Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
11/05/24 Unveiling Guardant Health (GH) Q3 Outlook: Wall Street Estimates for Key Metrics
11/01/24 Guardant Health to Participate in Upcoming Investor Conferences
10/30/24 Why Guardant Health Stock Was the Picture of Health Today
10/30/24 Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know
10/30/24 Guardant Health Named to TIME’s List of the Best Inventions of 2024
10/28/24 Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024
10/24/24 Roberto A. Mignone Joins Guardant Health Board of Directors
10/18/24 Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation?
10/15/24 Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
09/18/24 GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
GH Chatroom

User Image DeaconStocks Posted - 5 hours ago

$GH I'm out, good luck guys

User Image Kingsley1995 Posted - 5 hours ago

$GH I'm going to say it, all my optimism is gone. It's not looking good now. TMO will likely take a huge part of the market.

User Image Felix550 Posted - 5 hours ago

Saw TMO step into the CRC sector. $EXAS and $GH are going to crash soon with such competition. We're going to see $20 per share soon. I'm out now with a bit loss.

User Image Allie_Vo Posted - 5 hours ago

@rustycat The most important is Advanced Adenoma before people step into the cancer patient category. MYNZ has an 88% detection rate, while all others are only approved once you already HAVE IT, which you would know anyway. So all this sensitivity that you mentioned for those who already have it. But none of EXAS or GH can confirm advanced adenoma in the pre-cancer stage. This is important!!! $MYNZ $EXAS $GH

User Image Gator5326 Posted - 17 hours ago

$GH The New England Journal of Medicine, Guardant Health's Shield blood test for colorectal cancer screening demonstrated: 83.1% sensitivity for detecting colorectal cancer (95% confidence interval: 72.2% to 90.3%)4 87.5% sensitivity for detecting stage I, II, or III colorectal cancer4 90% specificity for advanced neoplasia14 The test's performance is considered comparable to other non-invasive screening methods, where overall sensitivity for detecting colorectal cancer ranges from 74% to 92%1. It's important to note that while the Shield test showed high sensitivity for colorectal cancer detection, its sensitivity for detecting advanced precancerous lesions was lower at 13.2%

User Image Gator5326 Posted - 17 hours ago

$GH quite the mistruth posted there, lol. Better do more homework on GH. πŸ€¦β€β™‚οΈ

User Image Allie_Vo Posted - 23 hours ago

$MYNZ check this out, comparison on CRC tests in US (who’s the leader???): Mainz Biomed costs $200 (88% detection) $GH Guardant Health costs $1,495 (20% detection) $EXAS Exact Sciences costs $500 (42% detection) Colonoscopy: $2,750 The average cost of a colonoscopy is $2,750, but the total can range from $1,250 to $4,800, depending on where you live, where you have the procedure performed and what your insurance covers (if you have insurance) $TMO partnership gonna change everything.

User Image nUme22 Posted - 1 day ago

$GH PUTs all over, i wonder why..

User Image TG770 Posted - 1 day ago

$GH beautiful cup and handle on the three months chart πŸ™Œ Let's see what happens πŸ˜‰ Keep calm and Breathe...

User Image First_Class_Seaman Posted - 1 day ago

$GH strong day today $ABVE cash on hand and acquisition coming

User Image Trader24s Posted - 2 days ago

$MYNZ Do you think $GH Guardant Health will reach the same level as other leading biotech companies? Guardant is in a strong position, but how does it compare within the broader biotech sector?

User Image ZRadly Posted - 1 week ago

$GH

User Image Pharmbird Posted - 1 week ago

$GH No comment ;)

User Image First_Class_Seaman Posted - 1 week ago

$ZONE shortie can't short more here. Chart proved how well it's hold at 2$ today $GH looking nice. Coming towards 35$

User Image Capitulation_0 Posted - 1 week ago

$KOD $ATYR $TGTX $GH all just beauties.. $CGEM is setting up...

User Image Cutlass Posted - 1 week ago

$GH πŸ‘πŸ”ŽπŸ“ˆ

User Image G101SPM Posted - 1 week ago

$GH $31.73 +2.00. * DAC (dollar average cost) (6) $26.46 last $23.00 (9.16.24). EXIT $50.00 (long term) BRIEF: Revenue rose 34% to $191.5 million for the three months ending in September, blasting through the $170 million that analysts were modeling. Guardant Health also posted a much smaller loss than its shareholders were expecting. It also boosted its full-year guidance. note: With a balance sheet flush with cash and a promising pipeline of clinical or biopharmaceutical tests, Guardant Health is justifying its $50.00 EXIT. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.

User Image Capitulation_0 Posted - 1 week ago

$TGTX $GH bucking the trend.. Bios selling off as usual.. Bios will come back someday. lol

User Image Jasooon Posted - 1 week ago

$EXAS $GH https://x.com/maxxchatsko/status/1854859161600770471?s=46&t=7vIazpOiaR63N_ccf3b54A

User Image Doozio Posted - 1 week ago

$GH 11/7 $frsh gap n go INTA πŸ§ β°β™ΎοΈ

User Image JFDI Posted - 1 week ago

$GH massive stage 1 base. Price curling hard off the gap low. Alerts at 33.69

User Image Gator5326 Posted - 1 week ago

$GH Buy When you see multiple insiders buy. πŸš€

User Image Gator5326 Posted - 1 week ago

$GH Some people are just laughable! $GH falling? I hope it β€œfalls” some more

User Image Metal_Health Posted - 1 week ago

$GH where did all the $EXAS blowhards go? Guardant will fly pass them in SP soon.

User Image Gator5326 Posted - 1 week ago

$GH C Suite and directors adding to their stacks. They know what time it is! πŸš€

User Image Metal_Health Posted - 1 week ago

@Paisley_W Thanks for the hot tip. I'll give up my future $70 gem $GH (SHIELD) for one that fetches a quarter about to be delisted and is being ticker spammed all over ST.

User Image Elephant_God Posted - 1 week ago

@longonly74 $EXAS Cologuard is not the only show in town and FIT and $GH compete for this market!

User Image Capitulation_0 Posted - 1 week ago

$GH $EXAS chart about to flip... funny.

User Image Gator5326 Posted - 1 week ago

$GH $EXAS knows $GH is taking market share and at a fast pace. Grab all the $GH you can. Long term play, imo

User Image Metal_Health Posted - 1 week ago

$GH patience grasshopper. This is a stock for 401K's but people like to swing it.

Analyst Ratings
UBS Buy Aug 21, 24
Piper Sandler Overweight Aug 13, 24
Citigroup Buy Aug 8, 24
TD Cowen Buy Aug 8, 24
Craig-Hallum Buy Aug 8, 24
JP Morgan Overweight Aug 8, 24
BTIG Buy Jul 30, 24
B of A Securities Buy Jul 18, 24
Goldman Sachs Buy Jul 17, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chudova Darya Chief Technology Off.. Chief Technology Officer Jan 16 Option 8.80 6,626 58,309 35,305 01/16/24
Joyce Meghan V. Director Director Dec 04 Sell 26.34 100 2,634 4,422 12/05/23
Joyce Meghan V. Director Director Dec 04 Option 0 66 4,522 12/05/23
Kalia Kumud Chief Information Of.. Chief Information Officer Dec 01 Sell 26.37 5,800 152,946 5,926 12/04/23
Kalia Kumud Chief Information Of.. Chief Information Officer Dec 01 Option 0 710 12,079 12/04/23
Chudova Darya Chief Technology Off.. Chief Technology Officer Nov 15 Option 8.80 4,000 35,200 27,683 11/16/23
Chudova Darya Chief Technology Off.. Chief Technology Officer Sep 28 Option 8.80 4,500 39,600 20,180 09/29/23
Kalia Kumud Chief Information Of.. Chief Information Officer Sep 12 Sell 32.59 2,125 69,254 7,813 09/13/23
Joyce Meghan V. Director Director Sep 04 Sell 35.01 100 3,501 4,323 09/06/23
Joyce Meghan V. Director Director Sep 04 Option 0 66 4,423 09/06/23
Joyce Meghan V. Director Director Jun 14 Sell 37.55 2,766 103,863 4,224 06/16/23
Joyce Meghan V. Director Director Jun 14 Option 0 5,531 6,990 06/16/23
Kalia Kumud Chief Information Of.. Chief Information Officer Jun 09 Buy 32.73 2,981 97,568 5,193 06/13/23
Eltoukhy Helmy Co-Chief Executive O.. Co-Chief Executive Officer Mar 14 Buy 26.24 93,052 2,441,684 2,049,238 03/16/23
Talasaz AmirAli Co-Chief Executive O.. Co-Chief Executive Officer Mar 13 Buy 25.74 97,000 2,496,780 24,250 03/15/23
Merrill Amelia SVP, People SVP, People Aug 11 Option 4.18 5,000 20,900 29,208 08/15/22
Merrill Amelia SVP, People SVP, People Aug 11 Sell 53.85 9,000 484,650 20,208 08/15/22
MERESMAN STANLEY J Director Director Mar 10 Option 5.94 4,934 29,308 8,993 03/14/22
MERESMAN STANLEY J Director Director Mar 10 Sell 58.74 4,934 289,823 4,059 03/14/22
MERESMAN STANLEY J Director Director Jan 10 Option 5.94 4,934 29,308 8,993 01/12/22
MERESMAN STANLEY J Director Director Jan 10 Sell 86.08 4,934 424,719 4,059 01/12/22
MERESMAN STANLEY J Director Director Dec 10 Option 5.94 4,934 29,308 8,993 12/14/21
MERESMAN STANLEY J Director Director Dec 10 Sell 95.59 4,934 471,641 4,059 12/14/21
Eltoukhy Helmy Co-Chief Executive O.. Co-Chief Executive Officer Nov 19 Buy 95.78 104,500 10,009,010 1,956,186 11/23/21
Talasaz AmirAli Co-Chief Executive O.. Co-Chief Executive Officer Nov 19 Buy 95.8 104,500 10,011,100 1,853,845 11/23/21
MERESMAN STANLEY J Director Director Oct 11 Option 5.94 4,934 29,308 8,993 10/13/21
MERESMAN STANLEY J Director Director Oct 11 Sell 103.59 4,934 511,113 4,059 10/13/21
MERESMAN STANLEY J Director Director May 12 Option 5.94 4,934 29,308 8,993 05/12/21
MERESMAN STANLEY J Director Director May 12 Sell 133.01 4,934 656,271 4,059 05/12/21
CLARK IAN T Director Director Apr 28 Option 4.18 538 2,249 5,181 04/28/21
CLARK IAN T Director Director Apr 28 Sell 159.92 538 86,037 4,643 04/28/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Apr 22 Sell 150.68 72,365 10,903,958 1,835,902 04/22/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Apr 14 Sell 155.52 239,649 37,270,212 2,167,429 04/14/21
MERESMAN STANLEY J Director Director Apr 14 Option 5.94 4,934 29,308 8,993 04/14/21
MERESMAN STANLEY J Director Director Apr 14 Sell 154.28 4,934 761,218 4,059 04/14/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Apr 09 Sell 159.1 220,685 35,110,984 2,407,078 04/09/21
CLARK IAN T Director Director Mar 29 Option 4.18 538 2,249 5,181 03/29/21
CLARK IAN T Director Director Mar 29 Sell 132.09 538 71,064 4,643 03/29/21
CLARK IAN T Director Director Mar 01 Option 4.18 538 2,249 5,181 03/01/21
CLARK IAN T Director Director Mar 01 Sell 154 538 82,852 4,643 03/01/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 12 Sell 168.73 6,613 1,115,811 470,800 02/12/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 12 Sell 162.35 292,773 47,531,697 477,413 02/12/21
MERESMAN STANLEY J Director Director Feb 12 Option 5.94 4,934 29,308 8,993 02/12/21
MERESMAN STANLEY J Director Director Feb 12 Sell 162.71 4,934 802,811 4,059 02/12/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 09 Sell 161.95 454,650 73,630,568 509,631 02/09/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 05 Sell 158.88 142,400 22,624,512 568,601 02/05/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 03 Sell 156.01 260,404 40,625,628 587,033 02/03/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Jan 26 Sell 159.03 160,886 25,585,701 2,627,763 01/26/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Jan 21 Sell 163.08 489,114 79,764,711 2,788,649 01/21/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Jan 19 Sell 158.57 150,000 23,785,500 514,020 01/19/21